Issue Contents
|
|
Marketing Authorisations
|
|
|
|
|
A single daily dose, but more dyskinesia
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No proven efficacy beyond a placebo effect
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
|
|
Cardiovascular assessment of dapagliflozin: no advance
|
|
|
|
|
|
|
|
|
|
Additive adverse effects when neuroleptics are combined
|
|
|
|
|
|
|
|
|
|
|
|
The complete contents of
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated.
